Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15,

CRANBURY, N.J., Nov. 15, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2011. Palatin reported a net loss of $3.4 million, or $(0.10) per basic and diluted share, for the quarter ended September 30, 2011, compared to a net loss of $4.6 million, or $(0.39) per basic and diluted share, for the same period in 2010.

The decrease in net loss for the quarter ended September 30, 2011, compared to the same period last fiscal year, is the result of Palatin's previously announced strategic decision to reduce staffing levels and to focus resources and efforts on clinical trials of bremelanotide and preclinical development of an inhaled formula of PL-3994 and a new peptide drug candidate for sexual dysfunction.  The decrease in net loss per share was also significantly impacted by the higher number of shares outstanding in the quarter ended September 30, 2011 compared to the same period last fiscal year due primarily to the sale of shares of stock in March 2011.

REVENUE

Revenues for the quarter ended September 30, 2011 were $27,000, compared to $216,000 for the same period in 2010, reflecting the decrease in revenue recognized under Palatin's agreements with AstraZeneca AB.

COSTS AND EXPENSES

Total operating expenses for the quarter ended September 30, 2011 were $3.4 million, compared to $4.8 million for the comparable quarter of 2010. The decrease in operating expenses for the quarter is the result of Palatin's previously announced strategic decision to reduce staffing levels and to focus resources and efforts on clinical trials of bremelanotide and PL-3994 and preclinical development of an inhaled formula of PL-3994 and a new peptide drug candidate for sexual dysfunction.

CASH POSITION

Palatin's cash and cash equivalents were $14.9 million as of September 30, 2011, compared to $18.9 million at June 30, 2011, with current liabilities of $1.7 million as of September 30, 2011 compared to $2.8 million as of June 30, 2011.

Palatin believes, based on its current operating plan, that its cash and cash equivalents will be sufficient to fund its operations through at least calendar year 2012.

CONFERENCE CALL / WEBCAST

Palatin will host a conference call and webcast on November 15, 2011 at 11:00 a.m. Eastern Time to discuss the results of operations in greater detail and an update on corporate developments.  Individuals interested in listening to the conference call live can dial 1-888-256-1007 (domestic) or 1-913-312-1466 (international), pass code 3249586. The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and webcast replay will be available approximately one hour after the completion of the call. To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), pass code 3249586.  The webcast and telephone replay will be available through November 22, 2011.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.  Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com.  

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, clinical trials and clinical trial results, collaborations with others, potential collaborations or agreements on its product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the Food and Drug Administration and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

PALATIN TECHNOLOGIES, INC.

and Subsidiary


Consolidated Statement of Operations

(unaudited)






Three Months Ended September 30,




2011


2010







REVENUES



$              27,217


$         216,147







OPERATING EXPENSES:






    Research and development



2,284,383


3,452,762

    General and administrative



1,109,382


1,381,776

         Total operating expenses



3,393,765


4,834,538







         Loss from operations



(3,366,548)


(4,618,391)







OTHER INCOME (EXPENSE):






    Investment income



15,040


20,375

    Interest expense



(2,973)


(2,304)

         Total other income, net



12,067


18,071







NET LOSS



$        (3,354,481)


$   (4,600,320)







Basic and diluted net loss per common share



$                 (0.10)


$            (0.39)







Weighted average number of common
shares outstanding used in
computing basic and diluted net loss
per common share



34,900,591


11,730,308




PALATIN TECHNOLOGIES, INC.

and Subsidiary


Consolidated Balance Sheets

(unaudited)



September 30,
2011


June 30,
2011

ASSETS





Current assets:





 Cash and cash equivalents


$          14,883,613


$        18,869,639

 Accounts receivable


-


131,149

 Prepaid expenses and other current assets


403,062


261,947

     Total current assets


15,286,675


19,262,735






Property and equipment, net


1,050,329


1,305,331

Restricted cash


350,000


350,000

Other assets


155,069


254,787

     Total assets


$          16,842,073


$        21,172,853






LIABILITIES AND STOCKHOLDERS' EQUITY





Current liabilities:





 Capital lease obligations


$                 30,078


$               34,923

 Accounts payable


336,206


496,908

 Accrued compensation


-


374,094

 Unearned revenue


18,888


46,105

 Accrued expenses


1,271,970


1,854,007

     Total current liabilities


1,657,142


2,806,037






Capital lease obligations


36,775


42,186

Deferred rent


100,589


132,855

     Total liabilities


1,794,506


2,981,078






Stockholders' equity:





 Preferred stock of $.01 par value – authorized 10,000,000 shares;





   Series A Convertible; issued and outstanding 4,997 shares
as of September 30, 2011 and June 30, 2011, respectively


50


50

 Common stock of $.01 par value – authorized 100,000,000
shares; issued and outstanding 34,900,591 as of
September 30, 2011 and June 30, 2011, respectively


349,006


349,006

 Additional paid-in capital


240,043,099


239,832,826

 Accumulated deficit


(225,344,588)


(221,990,107)

     Total stockholders' equity


15,047,567


18,191,775

     Total liabilities and stockholders' equity


$          16,842,073


$        21,172,853




SOURCE Palatin Technologies, Inc.

Read more on